List of Excipients in Branded Drug EPHEDRINE SULFATE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Akorn	EPHEDRINE SULFATE	ephedrine sulfate	17478-415	ACETIC ACID
Akorn	EPHEDRINE SULFATE	ephedrine sulfate	17478-415	SODIUM HYDROXIDE
Akorn	EPHEDRINE SULFATE	ephedrine sulfate	17478-415	WATER

Generic Drugs Containing EPHEDRINE SULFATE

Company	Ingredient	NDC	Excipient
Hikma Pharmaceuticals USA Inc	ephedrine sulfate	0641-6236	SODIUM CHLORIDE
Hikma Pharmaceuticals USA Inc	ephedrine sulfate	0641-6236	WATER
Hikma Pharmaceuticals USA Inc	ephedrine sulfate	0641-6238	ACETIC ACID

What are the Most Frequently-Used Excipients in EPHEDRINE SULFATE?

# Of NDCs	Excipient
25	ACETIC ACID
1	ANHYDROUS CITRIC ACID
2	NITROGEN

Ephedrine Sulfate Excipient Strategy and Commercial Opportunities

Last updated: August 16, 2026

Ephedrine sulfate is an established sympathomimetic with limited active-ingredient patent protection and low formulation complexity. Commercial value lies in injectable reliability, excipient compatibility, ready-to-administer packaging, shortage-resistant supply, and regulated distribution rather than in new-molecule exclusivity. The strongest opportunities are preservative-free sterile injections, premixed hospital presentations, differentiated oral dosage forms, and contract manufacturing for institutional buyers.

What is the current FDA status of ephedrine sulfate?

Ephedrine sulfate is FDA-approved in injectable and oral dosage forms. Its principal hospital use is the treatment of clinically important hypotension occurring in the setting of anesthesia. The reference injectable presentation is generally an ephedrine sulfate solution for intravenous or intramuscular administration at a concentration of 50 mg/mL.[1]

The product is a small-molecule generic drug, not a biologic. Biosimilar regulation does not apply. Market entry occurs through abbreviated new drug applications, and in some cases through a 505(b)(2) application for a materially differentiated dosage form, delivery system, or presentation.[2]

FDA dosage forms and commercial segments

Segment	Typical presentation	Main buyers	Commercial characteristics
Sterile injection	50 mg/mL single-dose vial or ampule	Hospitals, anesthesia departments, surgery centers	Highest technical barrier and strongest shortage value
Premixed injection	Ready-to-administer syringe or diluted bag	Hospitals and procedural settings	Reduces pharmacy preparation and dosing errors
Oral tablet	Commonly 25 mg or 50 mg strength	Retail, specialty and institutional pharmacies	Low manufacturing complexity and strong price competition
Combination products	Ephedrine-containing cold or respiratory products in some markets	Consumer and pharmacy channels	Subject to jurisdiction-specific restrictions
Bulk active ingredient	Ephedrine sulfate API	Finished-dose manufacturers	Controlled distribution and precursor regulation

FDA labeling for injectable ephedrine sulfate identifies water for injection and sodium chloride as core formulation components in commonly marketed products.[1] Exact excipient composition varies by manufacturer and dosage form.

What excipients are used in ephedrine sulfate formulations?

The simplest injectable formulation is an aqueous isotonic solution containing ephedrine sulfate, sodium chloride, and water for injection. The formulation target is chemical stability, acceptable osmolality, low particulate burden, sterility, and compatibility with the container-closure system.

Injectable excipient strategy

A practical injectable platform includes:

Formulation function	Candidate excipient or material	Strategic purpose
Vehicle	Water for injection	Primary solvent
Tonicity adjustment	Sodium chloride	Controls osmolality and injection tolerability
pH control	Hydrochloric acid or sodium hydroxide, where required	Maintains product pH during manufacture
Container protection	Type I glass or suitable polymer	Limits adsorption, extractables and leachables
Oxygen control	Nitrogen overlay or low-oxygen filling process	Reduces oxidative degradation risk
Microbial control	Aseptic processing and validated sterilization	Supports preservative-free hospital use
Dose presentation	Prefilled syringe, vial, ampule or bag	Reduces manipulation and preparation errors

Preservatives are generally unattractive for an injectable product intended for intravenous use, particularly where single-dose hospital administration is practical. A preservative-free product can support operating-room and anesthesia procurement, although the absence of preservative does not itself create durable intellectual-property protection.

The formulation development program should establish:

• pH range and drift during shelf life;
• assay and degradation-product profile;
• particulate and visible-inspection performance;
• compatibility with glass, elastomer and polymer components;
• adsorption to syringe and tubing materials;
• stability after dilution in commonly used infusion fluids;
• freeze-thaw and temperature excursion performance;
• container-closure integrity;
• photostability and oxygen sensitivity.

The FDA Inactive Ingredient Database can support excipient precedent and route-specific selection, but it does not replace product-specific safety, stability, compatibility and manufacturing data.[3]

Oral tablet excipient strategy

Oral ephedrine sulfate tablets are technically easier to manufacture. Conventional excipients can include lactose or another diluent, microcrystalline cellulose, starch or a disintegrant, povidone or another binder, and magnesium stearate or a comparable lubricant. The final selection depends on tablet strength, compressibility, dissolution, moisture sensitivity and target market.

Commercial differentiation can come from:

• immediate-release tablets with tighter content uniformity;
• orally disintegrating tablets for rapid administration;
• scored tablets for dose flexibility;
• low-moisture packaging;
• tamper-evident unit-dose blister packs;
• formulations that avoid a specific allergen or excipient concern;
• improved dissolution in a high-dose tablet.

The commercial ceiling for oral products is lower than for sterile injectables because the technology is familiar and multiple suppliers can reproduce the formulation.

What formulation patents protect ephedrine sulfate products?

The core ephedrine sulfate molecule is old, and broad composition-of-matter exclusivity is not a meaningful commercial barrier. A new entrant should assume that the active ingredient itself is available from multiple qualified sources, subject to regulatory controls and supply-chain qualification.

Potentially protectable subject matter includes:

1. A specific low-degradation injectable formulation.
2. A ready-to-administer diluted concentration.
3. A prefilled syringe or closed-system presentation.
4. A container-closure configuration that controls adsorption or leachables.
5. A manufacturing process that improves impurity control or sterilization yield.
6. A particular oral release profile.
7. A combination product with a distinct clinical use.
8. A device-linked delivery system.

The patent strength of a simple aqueous ephedrine sulfate solution is likely to be limited. A claim directed broadly to ephedrine sulfate, water and sodium chloride would face substantial prior-art and obviousness exposure. Stronger claims would require measurable technical results, such as materially improved stability, reduced impurity formation, lower adsorption, enhanced shelf life, or a demonstrated administration advantage.

How strong is the ephedrine sulfate patent estate?

Patent category	Expected commercial relevance	Assessment
Active ingredient composition patents	Very low	Historical technology with no meaningful new-molecule barrier
Basic aqueous solution	Low	Conventional excipient architecture
pH-controlled formulation	Low to moderate	Requires unexpected stability or impurity benefit
Prefilled syringe or ready-to-use product	Moderate	Product and device claims may create differentiation
Manufacturing process	Moderate	Stronger where impurity, yield or sterility benefits are demonstrated
Method of use	Low to moderate	Depends on a specific patient population or dosing protocol
Packaging and container closure	Moderate	Potentially useful, particularly for hospital presentations
Oral modified release	Moderate	Greater formulation complexity but limited market size

The most defensible portfolio would combine formulation, container-closure, process and device claims. A single broad formulation patent would provide limited protection against design-around strategies.

When does ephedrine sulfate lose exclusivity?

Ephedrine sulfate has no practical new-drug exclusivity barrier for standard generic presentations. Small-molecule exclusivity periods apply to qualifying new drug approvals, not to the historical active ingredient as a class.

A new 505(b)(2) product could potentially receive three years of regulatory exclusivity for a qualifying change supported by new clinical investigations essential to approval. Five-year new chemical entity exclusivity is not generally available for ephedrine sulfate because the active ingredient is established.[2]

Ephedrine sulfate exclusivity timeline

Rights category	Likely status
New chemical entity exclusivity	Not applicable to established ephedrine sulfate
Standard generic entry	Available subject to ANDA approval
Three-year 505(b)(2) exclusivity	Possible only for qualifying innovation and supporting clinical work
Orphan exclusivity	Not a normal commercial pathway for standard ephedrine sulfate
Pediatric exclusivity	Product-specific and not a core market assumption
Patent term extension	Relevant only to qualifying patents tied to an approved product
Biosimilar exclusivity	Not applicable

The commercial question is therefore not when the active ingredient loses exclusivity. It is whether a sponsor can create a defensible product-level position around presentation, formulation, device, process or supply reliability.

What is the Orange Book status of ephedrine sulfate?

FDA Orange Book treatment is product-specific. Listed products and patents must be reviewed by dosage form, strength, applicant and approval pathway. Standard ephedrine sulfate products are generally subject to ANDA competition rather than a durable branded patent strategy.[4]

Orange Book analysis should cover:

• approved reference-listed drugs;
• approved ANDAs;
• listed patents and pediatric exclusivity, if any;
• dosage-form-specific differences;
• therapeutic-equivalence codes;
• discontinued products that remain relevant to reference-product strategy.

A sponsor considering an injectable product should not assume that the absence of a broad active-ingredient patent eliminates all regulatory work. An ANDA still requires pharmaceutical equivalence, bioequivalence where applicable, manufacturing controls, sterility assurance, container-closure qualification and labeling conformity.

Which companies are challenging ephedrine sulfate products?

Ephedrine sulfate is a mature generic market. Competition is more likely to involve multiple ANDA applicants and contract manufacturers than high-profile Paragraph IV litigation.

What is the Paragraph IV risk?

Paragraph IV challenges are likely to be commercially relevant only where a newer branded or 505(b)(2) product obtains formulation, device or method-of-use patents. A standard generic injectable based on a conventional aqueous formulation would more commonly face ordinary ANDA competition and price erosion than patent litigation.

A Paragraph IV strategy could target:

• a listed formulation patent;
• a prefilled delivery system;
• a specific concentration or dilution;
• a method-of-use claim;
• a container-closure or stability claim.

For a product with narrow claims and limited commercial differentiation, the expected litigation value may be lower than the cost of developing a competing sterile product.

What excipient-based commercial opportunities exist?

1. Preservative-free injectable supply

Hospitals continue to value consistent access to essential injectable medicines. A supplier can compete through:

• single-dose vials with low overfill;
• terminally sterilized products where feasible;
• robust aseptic processing;
• dual-source excipient procurement;
• validated alternate container components;
• long-dated inventory;
• transparent shortage-response capacity.

FDA’s drug shortage resources identify supply interruptions and manufacturer status for affected medicines, making shortage resilience a potential procurement advantage.[5]

2. Ready-to-administer presentations

A prefilled syringe can reduce pharmacy compounding, preparation time and medication-error opportunities. The value proposition is strongest in anesthesia, emergency medicine and procedural care.

The development burden includes device compatibility, plunger and stopper extractables, dose accuracy, glide force, terminal sterilization or aseptic filling, human factors and stability in the final device. Device-linked claims may provide better protection than a conventional vial formulation.

3. Diluted and premixed products

A ready-to-use diluted ephedrine sulfate presentation may target facilities that prefer standardized administration concentrations. The product must address concentration clarity, labeling, infusion compatibility and protection against dosing confusion.

This opportunity requires careful regulatory positioning. A dilution change that does not materially improve clinical use may offer limited pricing power and may be vulnerable to rapid generic replication.

4. Hospital-focused packaging

Unit-dose cartons, barcode-ready labels, tamper evidence and standardized syringe dimensions can support institutional contracts. Packaging itself may not justify a premium, but it can improve formulary acceptance when combined with reliable supply and operating-room workflow benefits.

5. Excipient substitution and supply security

Excipient qualification is a practical commercial issue. Sodium chloride, elastomer components, glass, lubricants and packaging materials can become bottlenecks even when ephedrine sulfate API is available.

A sponsor can create value through:

• dual sourcing of pharmaceutical-grade sodium chloride;
• alternate stopper and syringe platforms;
• regional fill-finish capacity;
• validated formulation similarity across sites;
• lower dependence on a single glass or polymer supplier.

These measures are more likely to support supply contracts than patent royalties.

What manufacturing and regulatory barriers affect market entry?

Sterile manufacturing is the principal barrier for injectable ephedrine sulfate. The sponsor must control bioburden, endotoxin, particulate matter, sterility, fill accuracy, container-closure integrity and process reproducibility. FDA’s current good manufacturing practice requirements apply to excipient controls, component qualification, aseptic processing and finished-product release.[6]

Ephedrine also creates controlled-distribution and precursor-management issues. Regulatory requirements vary by jurisdiction and can affect API procurement, importation, storage, customer verification and transaction monitoring. In the United States, ephedrine-related chemicals are subject to federal controls intended to prevent diversion into illicit methamphetamine manufacture.[7]

Geographic expansion therefore requires more than a common dossier. Sponsors must review:

• controlled-substance or precursor rules;
• import and export licensing;
• local pharmacopoeial standards;
• preservative and excipient restrictions;
• hospital procurement rules;
• serialization and anti-counterfeiting requirements;
• local GMP inspection expectations.

How does ephedrine sulfate compare with competing vasopressors?

Ephedrine competes clinically with phenylephrine, norepinephrine and other agents used to manage perioperative hypotension. The products are not interchangeable in all settings because they differ in mechanism, dosing, onset, duration and effect on heart rate.

Product	Primary commercial differentiator	Excipient and packaging opportunity
Ephedrine sulfate	Mixed direct and indirect sympathomimetic activity	Prefilled syringes, preservative-free vials, ready-to-use dilution
Phenylephrine hydrochloride	Predominantly alpha-adrenergic activity	Standardized premixes and low-waste presentations
Norepinephrine products	High-acuity vasopressor use	Ready-to-administer bags and closed-system delivery
Epinephrine products	Broad emergency and critical-care use	Autoinjectors, prefilled syringes and stable premixes

Ephedrine’s opportunity is concentrated in anesthesia and perioperative care, where familiar dosing and rapid access can matter more than novel pharmacology.

What licensing deals and revenue opportunities exist?

The most plausible licensing structures involve product and manufacturing capabilities rather than the active ingredient:

• license of a prefilled syringe platform;
• contract development and manufacturing for sterile ephedrine sulfate;
• regional commercialization rights;
• supply agreements with hospital distributors;
• co-development of a ready-to-administer presentation;
• technology transfer for aseptic fill-finish;
• private-label supply for group purchasing organizations.

Public companies generally do not report ephedrine sulfate revenue as a separate line item. Revenue exposure is likely to be embedded within broader generic injectable, anesthesia or hospital-product segments. The product can still have strategic value when it improves portfolio breadth, hospital contract eligibility or manufacturing utilization.

What generic launch scenarios exist for ephedrine sulfate?

Standard vial launch

This is the fastest route but has the weakest differentiation. Price competition can be severe, and the product is vulnerable to substitution by other approved suppliers.

Prefilled syringe launch

This requires more development and device validation but can command better institutional interest. The commercial case depends on preparation savings, workflow integration and dependable supply.

Premixed bag launch

This may appeal to hospitals seeking standardized dosing and reduced pharmacy manipulation. Manufacturing, stability and labeling requirements are more demanding.

505(b)(2) differentiated launch

A sponsor could pursue a new presentation or delivery system supported by clinical or human-factors data. This creates a potential regulatory exclusivity pathway but carries materially higher development cost.

Key Takeaways

• Ephedrine sulfate has limited practical active-ingredient patent protection.
• The principal opportunity is product differentiation, not molecule exclusivity.
• Preservative-free sterile injections are the core commercial segment.
• Prefilled syringes, premixed products and hospital-ready packaging offer the strongest differentiation.
• A conventional aqueous formulation using sodium chloride and water for injection is unlikely to support broad, durable patent claims.
• Sterile manufacturing, container-closure qualification and supply reliability are the main barriers to entry.
• Biosimilar risk does not apply because ephedrine sulfate is a small-molecule drug.
• Paragraph IV exposure is likely to be product-specific and concentrated in newer formulation or device patents.
• Licensing value is most likely to arise from fill-finish capacity, delivery platforms and regional hospital distribution.
• A successful strategy should combine formulation claims, device claims, process controls and shortage-resilient supply.

FAQs

Can ephedrine sulfate be reformulated without sodium chloride?

Yes. A sponsor can evaluate alternative tonicity systems, but the substitute must meet osmolality, stability, tolerability, compatibility and regulatory requirements. Removing sodium chloride does not automatically create a patentable formulation.

Is ephedrine sulfate suitable for an orally disintegrating tablet?

Potentially. An orally disintegrating tablet could improve administration speed and convenience, but taste masking, dose uniformity, moisture protection and dissolution performance would determine commercial viability.

Can a prefilled ephedrine sulfate syringe receive new regulatory exclusivity?

Possibly. A 505(b)(2) pathway may be available if the product includes a qualifying innovation supported by new clinical investigations essential to approval. The exclusivity analysis is product-specific.[2]

Are ephedrine sulfate formulations subject to nitrosamine concerns?

Nitrosamine risk should be assessed as part of the API, excipient, water, packaging and manufacturing-process control strategy. The risk profile depends on raw materials, nitrite sources, amines, pH, temperature and storage conditions.

Which excipients should be prioritized for global sourcing?

Sodium chloride, water-system components, elastomers, glass, syringe polymers and lubricants should receive priority because they affect sterility, extractables, leachables, container closure and supply continuity.

References

1. U.S. Food and Drug Administration. (2024). Ephedrine sulfate injection prescribing information. DailyMed.
2. U.S. Food and Drug Administration. (2019). Applications covered by section 505(b)(2). FDA.
3. U.S. Food and Drug Administration. (2024). Inactive Ingredient Database. FDA.
4. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations. FDA.
5. U.S. Food and Drug Administration. (2025). Drug shortages. FDA.
6. U.S. Food and Drug Administration. (2024). Current good manufacturing practice for finished pharmaceuticals, 21 C.F.R. Parts 210 and 211. FDA.
7. U.S. Drug Enforcement Administration. (2024). Regulated chemicals and ephedrine controls. DEA.